DoH signs MoU with M42 and AbbVie. Credit: The Department of Health – Abu Dhabi/ PRNewswire.

The Department of Health Abu Dhabi (DoH) has signed a memorandum of understanding with integrated healthcare company M42 and AbbVie Biopharmaceuticals to advance personalised medicine and genomics in the city.

M42 was created through the combination of Mubadala Health and G42 Healthcare.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The collaboration aims to advance precision medicine for the diagnosis and treatment of non-small cell lung cancer (NSCLC) and multiple myeloma.

The DoH intends to advance research that will enable broad patient access to new approaches in healthcare, contributing to changes in policy and guideline implementation.

DoH Research and Innovation Center executive director Dr Asma Al Mannaei stated: “It is without a doubt that personalised medicine and genomics hold transformative potential to reshape the delivery of care and improve outcomes.

“Abu Dhabi continues to harness the power of these fields to unlock a new era of healthcare where every patient’s journey is guided by their own genetic blueprint, leading to enhanced quality of life and a brighter future for generations to come.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With a focus on precision medicine tailored to the needs of individuals, the partnership aims to progress the unique genomics programme of the United Arab Emirates and convert scientific advancements into tangible patient benefits.

Last year, Abu Dhabi introduced the first personalised precision medicine programme for oncology in the region, as part of its preventive healthcare efforts.

This programme includes personalised, predictive and precision medicine leveraging genomics to transform drug therapy, diagnostics and prevention.

AbbVie Gulf and Levant general manager Hassan Sabbah stated: “This partnership aims to advance precision medicine in diagnosis and treatment to help enable broader patient access in the UAE to innovative therapies.

“Our efforts are progressing to launch several initiatives that support research and clinical trials and develop innovative solutions to deal effectively with local and regional health needs, challenges and burdens.